Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Contineum Therapeutics, Inc. - Common stock (NQ:CTNM)

15.50 -0.43 (-2.70%)
Streaming Delayed Price Updated: 3:20 PM EDT, Aug 4, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Contineum Therapeutics, Inc. - Common stock

< Previous 1 2 3 Next >
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
 
Via Benzinga
News headline image
Contineum Therapeutics Provides Update on Phase 1b Positron Emission Tomography (PET) Trial of PIPE-791
From Contineum Therapeutics, Inc.
Via Business Wire
News headline image
Contineum Therapeutics to Present at the 2025 RBC Capital Markets Global Healthcare Conference
From Contineum Therapeutics, Inc.
Via Business Wire
News headline image
Contineum Therapeutics Reports First-Quarter 2025 Financial Results; Affirms Key Clinical Development Milestones
From Contineum Therapeutics, Inc.
Via Business Wire
News headline image
Contineum Therapeutics Appoints Timothy Watkins, M.D., M.Sc., as Chief Medical Officer and Head of Development
From Contineum Therapeutics, Inc.
Via Business Wire
News headline image
Contineum Therapeutics Announces Appointment of Diego Miralles, M.D. to Its Board of Directors
From Contineum Therapeutics, Inc.
Via Business Wire
News headline image
Contineum Therapeutics to Present at the Stifel 2025 Virtual CNS Forum
From Contineum Therapeutics, Inc.
Via Business Wire
News headline image
Contineum Therapeutics Reports Fourth-Quarter 2024 Financial Results; Affirms Key Clinical Development Milestones
From Contineum Therapeutics, Inc.
Via Business Wire
News headline image
Contineum Therapeutics Initiates Patient Dosing in Phase 1b Chronic Pain Trial of PIPE-791
From Contineum Therapeutics, Inc.
Via Business Wire
News headline image
Contineum Therapeutics to Present at the 2025 Leerink Partners Global Healthcare Conference
From Contineum Therapeutics, Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
New Oriental Education, Walgreens And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Contineum Therapeutics Completes Enrollment in Phase 2 PIPE-307 VISTA Trial for the Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS)
From Contineum Therapeutics, Inc.
Via Business Wire
News headline image
RAPT Therapeutics Names Lori Lyons-Williams Chair of the Company’s Board of Directors
From RAPT Therapeutics, Inc.
Via GlobeNewswire
News headline image
Contineum Therapeutics Initiates Patient Dosing in Phase 1b Positron Emission Tomography (PET) Trial of PIPE-791
From Contineum Therapeutics, Inc.
Via Business Wire
News headline image
Adobe, Keros Therapeutics, Lovesac And Other Big Stocks Moving Lower In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why DBV Technologies Shares Are Trading Higher By Around 37%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Contineum Therapeutics to Attend the 7th Annual Evercore HealthCONx Conference
From Contineum Therapeutics, Inc.
Via Business Wire
News headline image
Contineum Therapeutics Expands Clinical Development of PIPE-791 With FDA Authorization of Its Investigational New Drug (IND) Application for Chronic Pain
From Contineum Therapeutics, Inc.
Via Business Wire
News headline image
Contineum Therapeutics to Attend Upcoming Investor Conferences
From Contineum Therapeutics, Inc.
Via Business Wire
News headline image
Contineum Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
From Contineum Therapeutics, Inc.
Via Business Wire
News headline image
Contineum Therapeutics to Present at Multiple Upcoming Investor Conferences
From Contineum Therapeutics, Inc.
Via Business Wire
News headline image
CTNM Stock Earnings: Contineum Therapeutics Misses EPS for Q2 2024 ↗
CTNM stock results show that Contineum Therapeutics missed analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
News headline image
Contineum Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
From Contineum Therapeutics, Inc.
Via Business Wire
News headline image
Contineum Therapeutics Announces Publication of Encouraging Data in the Proceedings of the National Academy of Sciences on PIPE-307, Its M1 Receptor Selective Inhibitor, in Clinical Development for Relapse-Remitting Multiple Sclerosis
From Contineum Therapeutics, Inc.
Via Business Wire
News headline image
Contineum Therapeutics Announces Appointment of Sarah Boyce to Board of Directors
From Contineum Therapeutics, Inc.
Via Business Wire
News headline image
Contineum Therapeutics to Present at the 45th Annual Goldman Sachs Healthcare Conference
From Contineum Therapeutics, Inc.
Via Business Wire
News headline image
Contineum Therapeutics Announces Appointment of John Healy as General Counsel & Corporate Secretary
From Contineum Therapeutics, Inc.
Via Business Wire
News headline image
Contineum Therapeutics Announces Appointment of Troy Ignelzi to Board of Directors
From Contineum Therapeutics, Inc.
Via Business Wire
News headline image
Contineum Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
From Contineum Therapeutics, Inc.
Via Business Wire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.